Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study

By sjmartinez • November 17, 2022

Tamma PD, Komarow L, Ge L, Garcia-Diaz J, Herc ES, Doi Y, Arias CA, Albin O, Saade E, Miller LG, Jacob JT, Satlin MJ, Krsak M, Huskins WC, Dhar S, Shelburne SA, Hill C, Baum KR, Bhojani M, Greenwood-Quaintance KE, Schmidt-Malan SM, Patel R, Evans SR, Chambers HF, Fowler VG Jr, van Duin D; Antibacterial Resistance Leadership Group. Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study. Open Forum Infect Dis. 2022 Oct 27;9(11):ofac572. doi: 10.1093/ofid/ofac572. PMID: 36381622; PMCID: PMC9645644.

Tags: bacteremia, ceftriaxone, ESBL, Escherichia coli, Infectious Diseases, mortality, Publications, resistance

The obstacle is the way: Finding a path to hepatitis C elimination

Lo Re V 3rd, Price JC, Schmitt S, Terrault N, Bhattacharya D, Arohnson A. The obstacle is the way: Finding a path to hepatitis C[...]

Severe Acute Respiratory Syndrome Coronavirus 2 Infection Alters Mediators of Lung Tissue Remodeling In Vitro and In Vivo

Wong M, Gain C, Sharma MB, Fotooh Abadi L, Hugo C, Vassilopoulos H, Daskou M, Fishbein GA, Kelesidis T. Severe Acute Respiratory Syndrome Coronavirus 2[...]

Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman[...]